APYX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -32.54% compared to Apyx Medical's net margin of 4.8%. Apyx Medical's return on equity of -133.56% beat Baxter International's return on equity of -7.38%.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 220%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 25.91%. Given that Apyx Medical has higher upside potential than Baxter International, analysts believe Apyx Medical is more attractive than Baxter International.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3% to investors and pays a quarterly dividend of $0.17 per share. Apyx Medical pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are smaller than Baxter International quarterly revenues of $2.6B. Apyx Medical's net income of -$4.6M is lower than Baxter International's net income of $126M. Notably, Apyx Medical's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 1.32x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

electroCore has a net margin of -32.54% compared to Apyx Medical's net margin of -45.81%. Apyx Medical's return on equity of -133.56% beat electroCore's return on equity of -147.07%.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 220%. On the other hand electroCore has an analysts' consensus of $25.20 which suggests that it could grow by 270.04%. Given that electroCore has higher upside potential than Apyx Medical, analysts believe electroCore is more attractive than Apyx Medical.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison electroCore has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.354%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are larger than electroCore quarterly revenues of $7M. Apyx Medical's net income of -$4.6M is lower than electroCore's net income of -$3.2M. Notably, Apyx Medical's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 2.02x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -32.54% compared to Apyx Medical's net margin of -17.66%. Apyx Medical's return on equity of -133.56% beat KORU Medical Systems's return on equity of -32.71%.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 220%. On the other hand KORU Medical Systems has an analysts' consensus of $5.70 which suggests that it could grow by 109.56%. Given that Apyx Medical has higher upside potential than KORU Medical Systems, analysts believe Apyx Medical is more attractive than KORU Medical Systems.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.809%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are larger than KORU Medical Systems quarterly revenues of $8.8M. Apyx Medical's net income of -$4.6M is lower than KORU Medical Systems's net income of -$1.6M. Notably, Apyx Medical's price-to-earnings ratio is -- while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 3.70x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Owlet has a net margin of -32.54% compared to Apyx Medical's net margin of -44.19%. Apyx Medical's return on equity of -133.56% beat Owlet's return on equity of --.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 220%. On the other hand Owlet has an analysts' consensus of $10.17 which suggests that it could grow by 145.28%. Given that Apyx Medical has higher upside potential than Owlet, analysts believe Apyx Medical is more attractive than Owlet.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison Owlet has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Owlet pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are smaller than Owlet quarterly revenues of $20.5M. Apyx Medical's net income of -$4.6M is higher than Owlet's net income of -$9.1M. Notably, Apyx Medical's price-to-earnings ratio is -- while Owlet's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 0.59x for Owlet. Usually stocks with elevated PS ratios are considered overvalued.